{"id":"fluzone-im","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5853147","moleculeType":null,"molecularWeight":"381.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles or viral antigens that trigger both humoral and cellular immune responses. Upon intramuscular administration, the vaccine activates B cells to produce strain-specific antibodies and T cells to provide cellular immunity, thereby reducing the risk of infection and severe disease from circulating influenza viruses.","oneSentence":"Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:46.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT04537234","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-11-10","conditions":"Influenza (Healthy Volunteers)","enrollment":165},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06067555","phase":"EARLY_PHASE1","title":"Intradermal Influenza Vaccination","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-01-24","conditions":"Vaccine Reaction","enrollment":249},{"nctId":"NCT06582277","phase":"PHASE2","title":"Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836","status":"COMPLETED","sponsor":"Osivax","startDate":"2024-10-22","conditions":"Vaccine-Preventable Diseases, Influenza","enrollment":117},{"nctId":"NCT03898986","phase":"PHASE1","title":"The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-10-08","conditions":"Influenza","enrollment":18},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT05116917","phase":"PHASE2","title":"Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2021-11-05","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT05060887","phase":"PHASE2","title":"Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2021-11-15","conditions":"Influenza","enrollment":239},{"nctId":"NCT03739112","phase":"PHASE3","title":"Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly","status":"COMPLETED","sponsor":"Medicago","startDate":"2018-09-18","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":12794},{"nctId":"NCT02918006","phase":"PHASE2","title":"A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-08-31","conditions":"Influenza","enrollment":179},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT03283319","phase":"PHASE2","title":"Panblok H7 Vaccine Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":366},{"nctId":"NCT03453801","phase":"PHASE1","title":"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-30","conditions":"Influenza, Healthy","enrollment":80},{"nctId":"NCT03088904","phase":"PHASE1","title":"Genetic and Environmental Factors in the Response to Influenza Vaccination","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-10-03","conditions":"Influenza, Healthy","enrollment":109},{"nctId":"NCT00694213","phase":"PHASE1","title":"Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)","status":"COMPLETED","sponsor":"Vical","startDate":"2007-08","conditions":"Influenza","enrollment":47},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT01974895","phase":"PHASE2","title":"Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-23","conditions":"Influenza","enrollment":316},{"nctId":"NCT02242643","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":2432},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390},{"nctId":"NCT00693706","phase":"PHASE1","title":"Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-02","conditions":"Influenza","enrollment":200},{"nctId":"NCT02207413","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-18","conditions":"Influenza","enrollment":1886},{"nctId":"NCT02141581","phase":"PHASE4","title":"Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-08","conditions":"Influenza","enrollment":86},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792},{"nctId":"NCT03266237","phase":"PHASE4","title":"The Immune Response to Influenza Vaccinations in Elderly Individuals","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2013-12","conditions":"Influenza","enrollment":240},{"nctId":"NCT00727428","phase":"PHASE1","title":"Immunogenicity and Safety of GSK Biologicals' FluLaval® TF","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-08-05","conditions":"Influenza","enrollment":110},{"nctId":"NCT01665807","phase":"PHASE4","title":"A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine","status":"COMPLETED","sponsor":"Brenda Coleman","startDate":"2012-09","conditions":"Influenza, Vaccination Site Reactions (HT)","enrollment":868},{"nctId":"NCT02563093","phase":"PHASE4","title":"Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":208},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT00623181","phase":"PHASE2","title":"Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-01","conditions":"Influenza","enrollment":110},{"nctId":"NCT00391053","phase":"PHASE3","title":"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3851},{"nctId":"NCT01011049","phase":"PHASE2","title":"Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza","enrollment":1250},{"nctId":"NCT00755274","phase":"PHASE4","title":"Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":32},{"nctId":"NCT01181323","phase":"PHASE2","title":"Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Influenza","enrollment":240},{"nctId":"NCT00287092","phase":"PHASE3","title":"Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-02","conditions":"Pertussis, Diphtheria, Tetanus","enrollment":807},{"nctId":"NCT01405885","phase":"PHASE1","title":"A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2011-05","conditions":"Healthy","enrollment":116},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT00775450","phase":"PHASE2","title":"Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Influenza, Orthomyxovirus Infection, Myxovirus Infection","enrollment":807},{"nctId":"NCT01732198","phase":"PHASE2","title":"A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2013-03","conditions":"Infectious Disease","enrollment":220},{"nctId":"NCT00253734","phase":"PHASE2","title":"Immunogenicity and Safety of Different Doses of Fluzone® Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11","conditions":"Influenza","enrollment":217},{"nctId":"NCT01164553","phase":"PHASE1","title":"Comparison of Flu Vaccine Doses in Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-10","conditions":"Influenza","enrollment":243},{"nctId":"NCT00388583","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":817},{"nctId":"NCT01151059","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":138},{"nctId":"NCT01333462","phase":"PHASE1","title":"Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008","status":"COMPLETED","sponsor":"NanoBio Corporation","startDate":"2009-03","conditions":"Healthy Adult Volunteers","enrollment":199},{"nctId":"NCT00936468","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects","status":"COMPLETED","sponsor":"Colby Pharmaceutical Company","startDate":"2009-09","conditions":"Influenza","enrollment":472},{"nctId":"NCT00662272","phase":"PHASE1","title":"Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant","status":"COMPLETED","sponsor":"Colby Pharmaceutical Company","startDate":"2008-06","conditions":"Influenza","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trivalent inactivated influenza vaccine (TIV)","FDA-licensed seasonal influenza vaccine"],"phase":"marketed","status":"active","brandName":"Fluzone® (IM)","genericName":"Fluzone® (IM)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}